cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.3886/e240268v2
title: Global dataset on the effects of climate change on ecosystem goods and services (EGS) compiled from English language papers published between 2014 and 2018

description: Climate change is a pervasive and growing global threat to the supply and demand of ecosystem goods and services that maintain human well-being. A recent review found that the impacts of climate change on ecosystem services are sometimes mixed, posing challenges for managers who need to adapt to these changes. We expand on earlier work by exploring drivers of varying responses of ecosystem services to climate within studies. We conducted a systematic review of English-language papers directly assessing climate change impacts on the supply, demand, or monetary value of ‘provisioning services’, ‘regulating services’, or ‘cultural services’. Ultimately, we extracted data from 44 papers published from December 2014 to March 2018. In addition to recording direct climate impacts, we extracted data regarding climate interactions with non-climate drivers (e.g., land use change), study context (e.g., spatial scale, location, ecosystem) and methodology, characteristics and interactions between services, whether and how uncertainty was assessed, and implications for decision-making. To answer our core research question, we extracted data reflecting drivers of mixed responses (e.g., variation in ecosystem service responses over space, ecosystem service indicators, time periods, or climate change scenarios, models or variables). While biased and constrained by excluding articles published in non-English languages and grey literature, this data spreadsheet compiles summary information and relevant literature for managers, decision-makers, researchers, and planners.<br><br>Purpose<br>The compiled data underlie a synthesis of recent and future climate effects on ecosystem service supply, demand, and monetary value. By integrating information from recent publications, the data spreadsheet and associated synthesis update and extend previous literature reviews (particularly, Runting et al., 2017). The data spreadsheet also represents a literature library of climate impacts on ecosystem services, which can be aggregated or disaggregated by study areas and methodologies, ecosystem service features and interactions, drivers of variation in ecosystem service responses, climate and non-climate driver interactions, uncertainty assessment approaches, and decision-making implications. Research gaps discerned from the data (e.g., described in the synthesis paper) can inform crucial directions for future studies. In addition to supporting analyses that yield valuable summaries for practitioners (e.g., managers, decision-makers, planners), this literature library can be a source of context-relevant case studies for ensuring continued flows of nature’s benefits to people in an uncertain and changing climate.
DOI: 10.15468/dl.p5vz5c
title: Occurrence Download

description: A dataset containing 29042 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-98.43542 29.35626,-98.43542 29.49135,-98.57493 29.49135,-98.57493 29.35626,-98.43542 29.35626))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Magnoliopsida"
 ]
}

 The dataset includes 29042 records from 58 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0033509-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/pr00004368.0
title: Available datapackage for study 'Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder'

description: The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment.
DOI: 10.20366/unimib/unidata/sn261-1.0
title: Transgender Italy (2023-2024)
title: Transgender Italia (2023-2024)

description: The Transgender Italy dataset was produced as part of an Italian Master's thesis project entitled "Transgender: a quantitative look at discrimination, gender affirmation, and life satisfaction". The project had a twofold objective: on the one hand, to provide a quantitative description of the experiences of Italian transgender people in terms of discrimination, gender affirmation path and self-determination; on the other hand, to study the effect of the gender affirmation path on transgender people's satisfaction, taking into account the dimension of self-determination and the heterogeneity of experiences.<br>
<br>
The dataset includes data collected through an online questionnaire administered to 132 Italian transgender adults. Given the characteristics of the target population, sampling is not probabilistic.<br>
<br>
The questions are divided into four sections:<br>

- demographic information: age, place of residence, education, employment status and economic condition;<br>
- discrimination experienced as a transgender person: in general terms and in seven specific areas of social life;<br>
- path to gender affirmation;<br>
- quality of social relations and the attachment to the transgender community.<br>
description: Analysis Unit: individual<br>Universe: residents in Italy aged 18 and over who identify as a gender other than the one assigned at birth<br>Sample Procedure: 132 individuals. Non-probability sample of availability<br>Weight: No weight used<br>Collection Mode: web-based self-administered questionnaire (CAWI)
DOI: 10.7914/3fhv-jr22
title: Desert Peak EGS

description: Desert Peak EGS
DOI: 10.15468/dl.b9gntf
title: Occurrence Download

description: A dataset containing 1074 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Colombia",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is one of (Nymphargus ruizi, Nymphargus, Nymphargus ocellatus, Nymphargus griffithsi, Nymphargus mixomaculatus, Nymphargus grandisonae, Nymphargus lindae, Nymphargus bejaranoi, Nymphargus truebae, Nymphargus phenax)"
 ]
}

 The dataset includes 1074 records from 42 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0033511-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17574041
title: Data from "Room temperature nonlocal detection of charge-spin interconversion in a topological insulator"

description: This repository contains the source data from all experiments presented in the paper ''Room temperature nonlocal detection of charge-spin interconversion in a topological insulator'' and its Supplementary information file.

The experimental data is organized in Excel files, each named after the corresponding figure number. The Excel files each contain multiple sheets, with each sheet representing a specific subfigure from that figure. The sheets are labeled with the respective figure and subfigure numbers.
DOI: 10.5281/zenodo.17574040
title: Data from "Room temperature nonlocal detection of charge-spin interconversion in a topological insulator"

description: This repository contains the source data from all experiments presented in the paper ''Room temperature nonlocal detection of charge-spin interconversion in a topological insulator'' and its Supplementary information file.

The experimental data is organized in Excel files, each named after the corresponding figure number. The Excel files each contain multiple sheets, with each sheet representing a specific subfigure from that figure. The sheets are labeled with the respective figure and subfigure numbers.
DOI: 10.15468/dl.z2cnz6
title: Occurrence Download

description: A dataset containing 13 species occurrences available in GBIF matching the query:
{
 "and" : [
 "OccurrenceStatus is Present",
 "TaxonKey is Glyptemys muhlenbergii",
 "Year 2020-2025"
 ]
}

 The dataset includes 13 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0033513-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.7910/dvn/xfnoj6
title: Replication Files for “In Money, We Survive: The Effects of Social Security Retirement Income on Longevity”

description: This folder contains the replication data and code for the paper “In Money, We Survive: The Effects of Social Security Retirement Income on Longevity.”
DOI: 10.15468/dl.cyqd7q
title: Occurrence Download

description: A dataset containing 1529 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Crassula helmsii)",
 "BasisOfRecord is one of (Observation, Human Observation, Material sample, Specimen, Unknown evidence, Machine Observation, Occurrence evidence)",
 "Year is greater than or equal to 2016",
 "Year is less than or equal to 2025",
 "HasCoordinate is true",
 "Country is United Kingdom of Great Britain and Northern Ireland"
 ]
}

 The dataset includes 1529 records from 43 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0033514-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30607466
title: The raw data of NGS of bystander and Off-target effects in monkey in extended data fig.10c-j.

description: To demonstrate that TeABE also functions in a non-human primate model, we performed next-generation sequencing on <i>Macaca mulatta</i> to examine base editing at the CHD3 bystander site and the most likely off-target site, OT1, in both virus-injected and uninjected samples. The results revealed a significant increase in base editing efficiency at both the on-target locus and OT1 following viral injection.
DOI: 10.6084/m9.figshare.30607466.v1
title: The raw data of NGS of bystander and Off-target effects in monkey in extended data fig.10c-j.

description: To demonstrate that TeABE also functions in a non-human primate model, we performed next-generation sequencing on <i>Macaca mulatta</i> to examine base editing at the CHD3 bystander site and the most likely off-target site, OT1, in both virus-injected and uninjected samples. The results revealed a significant increase in base editing efficiency at both the on-target locus and OT1 following viral injection.
DOI: 10.15468/dl.89nmjj
title: Occurrence Download

description: A dataset containing 121 species occurrences available in GBIF matching the query:
{
 "and" : [
 {
 "or" : [
 "PublishingCountry is Colombia",
 {
 "and" : [
 "Country is Colombia",
 {
 "not" : {
 "Issue" : [
 "is Country coordinate mismatch"
 ]
 }
 }
 ]
 }
 ]
 },
 {
 "and" : [
 "TaxonKey is one of (Eremophilus mutisii [GBIF Backbone Taxonomy])",
 {
 "or" : [
 "Year is 2017",
 "Year is 2018",
 "Year is 2019",
 "Year is 2020",
 "Year is 2021",
 "Year is 2022",
 "Year is 2023",
 "Year is 2024"
 ]
 }
 ]
 }
 ]
}

 The dataset includes 121 records from 10 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0033515-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.p9hvgt
title: Occurrence Download

description: A dataset containing 121 species occurrences available in GBIF matching the query:
{
 "and" : [
 {
 "or" : [
 "PublishingCountry is Colombia",
 {
 "and" : [
 "Country is Colombia",
 {
 "not" : {
 "Issue" : [
 "is Country coordinate mismatch"
 ]
 }
 }
 ]
 }
 ]
 },
 {
 "and" : [
 "TaxonKey is one of (Eremophilus mutisii [GBIF Backbone Taxonomy])",
 {
 "or" : [
 "Year is 2017",
 "Year is 2018",
 "Year is 2019",
 "Year is 2020",
 "Year is 2021",
 "Year is 2022",
 "Year is 2023",
 "Year is 2024"
 ]
 }
 ]
 }
 ]
}

 The dataset includes 121 records from 10 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0033516-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/pr00006499
title: Predictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer_012021

description: Breast cancer is the most commonly occurring cancer in women and the second most common cancer overall. There were over 2 million new cases in 2018. There are many important medicines used in the treatment of breast cancer. However, response and toxicity to many therapies is highly unpredictable. For example, over half the eligible patients do not respond to anti-human epidermal growth factor receptor 2 (HER2) targeted therapy when used in the treatment of advanced breast cancer. Thus, more research is required to confirm and explore novel predictive markers of therapeutic and adverse effects of medicines used in the treatment of breast cancer.
Using the diverse range of data collected from clinical trials, it is possible to develop clinical tools that enable improved prediction of therapeutic and adverse outcomes of patients using medicines in the treatment of breast cancer. Being able to identify the expected response and adverse effect profile may enable patients and clinicians to make better decisions regarding whether to commence, continue, discontinue or change dosing of medicines used in the treatment of breast cancer.
DOI: 10.25934/00001483
title: A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer

description: The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer.
DOI: 10.25934/00003604
title: LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment

description: To investigate the efficacy and safety of BIBW 2992 in combination with vinorelbine i.v. chemotherapy as treatment in patients with HER2-overexpressing, metastatic breast cancer, who failed one prior trastuzumab (Herceptin®) treatment
DOI: 10.25934/00003649
title: Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy

description: The aim of this study is to investigate the efficacy and safety of afatinib alone or in combination with vinorelbine, as treatment in patients with HER2-overexpressing metastatic breast cancer, who have progressive brain lesions after trastuzumab and/or lapatinib based therapy
DOI: 10.25934/00004363
title: Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer

description: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if paclitaxel is more effective with or without gemcitabine for advanced breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel with or without gemcitabine in treating women who have advanced breast cancer.
DOI: 10.25934/00004520
title: A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

description: The main purpose of this study is to evaluate whether the study drug known as abemaciclib is effective in treating participants with breast cancer who have already tried other drug treatments.
DOI: 10.25934/00005577
title: A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF (Bevacizumab), in Combination With Capecitabine Chemotherapy, in Subjects With Previously Treated Metastatic Breast Cancer

description: This Phase III, multicenter, randomized, active-controlled, open-label trial is designed to evaluate the efficacy, safety, and pharmacokinetics of rhuMAb VEGF when combined with capecitabine compared with capecitabine alone in subjects with previously treated metastatic breast cancer.
DOI: 10.25934/00005579
title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

description: This is a Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of bevacizumab administered in combination with paclitaxel in patients with previously untreated, locally recurrent, or metastatic HER2-negative breast cancer. Patients will be randomized to one of two treatment arms: bevacizumab or placebo. All patients will be given an intravenous (IV) infusion of of paclitaxel (90 mg/m2) for 3 weeks during each 28-day cycle. bevacizumab or placebo (10 mg/kg) will be administered by IV infusion on Days 1 and 15 of each 28-day cycle. Patients will be treated until disease progression, unacceptable toxicity or death from any cause occurs.
DOI: 10.25934/00005597
title: A Randomized, Multi-Center Cross-Over Study to Evaluate Patient Preference and Health Care Professional (HCP) Satisfaction With Subcutaneous (SC) Administration of Trastuzumab in HER2-Positive Early Breast Cancer (EBC)

description: This randomized, open-label, crossover study will evaluate participants' preference and healthcare professional (HCP) satisfaction with SC versus IV Herceptin administration in HER2-positive early breast cancer. Participants will be randomized to receive either SC Herceptin or IV Herceptin every 3 weeks for Cycles 1 to 4, followed by crossover to the other treatment administration for Cycles 5 to 8. For up to 10 additional cycles (for a total of 18 cycles), participants will receive IV or SC Herceptin every 3 weeks.
DOI: 10.25934/00005635
title: Chemotherapy and Antibody Response Evaluation (CARE): A phase III, multinational, randomized study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) combined with chemotherapy in patients with HER2 overexpression who have not received cytotoxic chemotherapy for metastatic breast cancer.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00005636
title: A multinational open-label study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2lneu overexpression who have relapsed following one or two cytotoxic chemotherapy regimens for metastatic breast cancer.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00005638
title: An open-label extension study with recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) for patients whose metastatic breast cancer progressed during treatment on protocol H0648g.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00005639
title: A multicenter, expanded access, open-label safety study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2 overexpression who relapsed following multiple cytotoxic chemotherapy regimens for metastatic breast cancer.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00005665
title: A Randomized, Open-label Study of the Effect of Adjuvant Therapy With Adriamycin Plus Cytoxan Followed by Taxotere or Taxotere Plus Xeloda on Overall Survival in Female Patients With High-risk Breast Cancer

description: This 2 arm study will compare the efficacy and safety of Taxotere + Xeloda, versus Taxotere alone, following a regimen of Adriamycin plus Cytoxan in women with high-risk breast cancer. Following 4 cycles of Adriamycin and Cytoxan, patients will be randomized to receive either 1)Taxotere 75mg/m2 iv on day 1 and Xeloda 825mg/m2 po bid on days 1-14 of each 3 week cycle or 2) Taxotere 100mg/m2 iv alone on day 1 of each 3 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is 500+ individuals.
DOI: 10.25934/00005685
title: A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer

description: This is a Phase III, multicenter, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy compared with chemotherapy alone in subjects with previously untreated metastatic breast cancer.
DOI: 10.25934/00005688
title: A Phase III, Multicenter, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Treated Metastatic Breast Cancer

description: This phase III, multicenter, randomized, placebo-controlled, blinded trial is designed to evaluate the efficacy and safety of bevacizumab when combined with standard chemotherapy compared with chemotherapy alone in subjects with previously treated metastatic breast cancer.